Ceftazidime


Full Generic Medicine Info
Dosage/Direction for Use

Parenteral
Septicaemia
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Skin and soft tissue infections
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Respiratory tract infections
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Meningitis
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Bacteraemia
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Bone and joint infections
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Gastrointestinal infections
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Febrile neutropenia
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Abdominal infections
Adult: Dosage depends on the severity, sensitivity, site and type of infection. Dose range: 1-6 g daily in 2-3 divided doses. Usual dose for most infections: 1 g 8 or 12 hourly or 2 g 12 hourly. Severe infections (especially in immunocompromised patients): 2 g 8 or 12 hourly or 3 g 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Urinary tract infections
Adult: 0.5 g or 1 g 12 hourly. For complicated cases: 1-2 g 8 or 12 hourly. Doses may be given via IV inj, IV infusion or deep IM inj. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.

Parenteral
Pseudomonal lung infections in cystic fibrosis
Adult: 100-150 mg/kg daily in 3 divided doses via IV inj, IV infusion or deep IM inj. Max: 9 g daily. Consideration must be given to local treatment guidelines.
Child: 0-2 months 25-60 mg/kg daily in 2 divided doses; >2 months 30-100 mg/kg daily in 2-3 divided doses; up to 150 mg/kg daily (Max 6 g daily) in 3 divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis. Consideration must be given to local treatment guidelines.
Elderly: >80 years Max: 3 g daily.
Renal impairment: Severe infections: Increase unit dose by 50% or increase dosing frequency. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
CrCl (ml/min)Dosage Recommendation
<5Loading: 1 g. Maintenance: 0.5 g 48 hourly.
6-15Loading: 1 g. Maintenance: 0.5 g 24 hourly.
16-30Loading: 1 g. Maintenance: 1 g 24 hourly.
31-50Loading: 1 g. Maintenance: 1 g 12 hourly.

Reconstitution: Instructions for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Incompatibility: Incompatible with aminoglycosides; should not be mixed in the same giving set or syringe. Precipitation may occur when vancomycin is added to ceftazidime in solution.
Contraindications
Hypersensitivity to ceftazidime and other cephalosporins, or history of severe hypersensitivity to any other type of β-lactam antibacterial agents (e.g. penicillins, monobactams, carbapenems).
Special Precautions
Patient with history of gastrointestinal disease, particularly colitis; history of seizure disorder. Renal impairment. Neonates, children, and elderly. Pregnancy and lactation. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor renal function. Assess for signs and symptoms of anaphylaxis during 1st dose; nephrotoxicity, neurotoxicity, severe or bloody diarrhoea.
Adverse Reactions
Significant: Diarrhoea, increased INR; overgrowth of non-susceptible organisms (prolonged use). Blood and lymphatic system disorders: Eosinophilia, thrombocytosis. General disorders and administration site conditions: Phlebitis or thrombophlebitis (IV); pain or inflammation (IM). Investigations: Transient elevations in ALT, AST, lactate dehydrogenase, gamma-glutamyl transferase and alkaline phosphatase. Skin and subcutaneous tissue disorders: Maculopapular or urticarial rash.
Potentially Fatal: Severe hypersensitivity reactions; antibacterial agent-associated colitis and pseudomembranous colitis; haemolytic anaemia.
Drug Interactions
Concurrent administration of nephrotoxic agents such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function. Antagonistic effect with chloramphenicol. Ceftazidime may affect the gut flora, resulting in decreased reabsorption of estrogen and reduced efficacy of combined oral contraceptives.
Lab Interference
May cause false-positive urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution); false-positive serum or urine creatinine with Jaffe reaction. May cause positive Coombs' test.
Action
Ceftazidime binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall. This results in the inhibition of cell wall biosynthesis, leading to bacterial cell lysis and death.
Absorption: Time to peak plasma concentration: Approx 1 hour.
Distribution: Widely distributed throughout the body including bone, bile, skin, heart, pleural or lymphatic fluids, and CSF (higher concentrations achieved in inflamed meninges). Crosses the placenta and enters breast milk. Plasma protein binding: Approx 10%.
Metabolism: Not metabolised.
Excretion: Mainly via urine (approx 80-90% as unchanged drug). Elimination half-life: Approx 2 hours.
Storage
Parenteral: Store between 20-25°C. Protect from light.
CIMS Class
Cephalosporins
ATC Classification
J01DD02 - ceftazidime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on ceftazidime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in